Summary
Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor. All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers. However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.
Key Highlights
- 1All incumbent directors were re-elected to the Board with strong "For" vote majorities.
- 2KPMG LLP was ratified as Pfizer's independent registered public accounting firm for the 2026 fiscal year with significant shareholder approval.
- 3The amended Pfizer Inc. 2019 Stock Plan was approved by shareholders.
- 4Shareholders provided advisory approval for the compensation of Named Executive Officers.
- 5A shareholder proposal to Adopt An Independent Chair Policy was not approved.
- 6The Annual Meeting of Shareholders took place on April 23, 2026.